Urine monitoring of diazepam abuse - New intake or not?

Journal of Analytical Toxicology

Volumn 32, Issue 6, 2008, Pages 402-407

  Lennestål, Roland ^a   Lakso, Hans Åke ^a   Nilsson, Mats ^b   Mjörndal, Tom ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b Academy for Healthcare   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; CREATININE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DIAZEPAM; DRUG METABOLITE; ZOLPIDEM;

ADULT; ARTICLE; CASE REPORT; CREATININE URINE LEVEL; DRUG ABUSE; DRUG ELIMINATION; DRUG INTERACTION; DRUG SCREENING; DRUG URINE LEVEL; ENZYME METABOLISM; FEMALE; GAS CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PHARMACOGENETICS; URINALYSIS;

EID: 48249153423     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/32.6.402     Document Type: Article

References (32)

1. P. Lafolie. Knarkanalyser i Urin (Drug Analyses in Urine). Con Temp, Stockholm, Sweden, 1992, p 239.
2. K. Wolff, M. Farrell, J. Marsden, M.G. Monteiro, R. Ali, S. Welch, and J. Strang. A review of biological indicators of illicit drug use, practical considerations and clinical usefulness. Addiction 94(9): 1279-1298 (1999).
3. D. Simpson, R.A. Braithwaite, D.R. Jarvie, M.J. Stewart, S. Walker, I.W. Watson, and B. Widdop. Screening for drugs of abuse (II): cannabinoids, lysergic acid diethylamide, buprenorphine, methadone, barbiturates, benzodiazepines and other drugs. Ann. Clin. Biochem. 34(Pt 5): 460-510 (1997).
4. R.S. Braithwaite, D.R. Jarvie, P.S. Minty, S. Simpson, and B. Widdop. Screening for drugs of abuse. I: opiates, amphetamines and cocaine. Ann. Clin. Biochem. 32(Pt 2): 123-153 (1995).
5. A. Reiter, J. Hake, C. Meissner, J. Rohwer, H.J. Friedrich, and M. Oehmichen. Time of drug elimination in chronic drug abusers. Case study of 52 patients in a "low-step" detoxification ward. Forensic Sci. Int. 119(2): 248-253 (2001).
6. T.R. Harrison and E. Braunwald. Harrison's Principles of Internal Medicine. McGraw-Hill, New York, NY, 2001.
7. P. Lafolie, O. Beck, P. Hjemdahl, and S. Borg. Using relation between urinary cannabinoid and creatinine excretions to improve monitoring of abuser adherence to abstinence. Clin. Chem. 40(1): 170-171 (1994).
8. L. Bertilsson, T.K. Henthorn, E. Sanz, G. Tybring, J. Sawe, and T. Villen. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not de-brisoquin, hydroxylation phenotype. Clin. Pharmacol. Ther. 45(4): 348-355 (1989).
9. A. Smith-Kielland, B. Skuterud, K.M. Olsen, and J. Morland. Urinary excretion of diazepam metabolites in healthy volunteers and drug users. Scand. J. Clin. Lab. Invest. 61(3): 237-246 (2001).
10. M. Mandelli, G. Tognoni, and S. Garattini. Clinical pharmacokinetics of diazepam. Clin. Pharmacokinet. 3(1): 72-91 (1978).
11. C.S. Frings, R.M. White, and D.J. Battaglia. Status of drugs-of-abuse testing in urine: an AACC study. Clin. Chem. 33(9): 1683-1686 (1987).
12. C.S. Frings, D.J. Battaglia, and R.M. White. Status of drugs-of-abuse testing in urine under blind conditions: an AACC study. Clin. Chem. 35(5): 891-894 (1989).
13. M. Sundgren, K. Hedenmalm, and O. Spigset. Confirmation of urinary benzodiazepines using solid-phase extraction and GC-MS. Analyt. Pharmacol. 1: 78-82 (2000).
14. S. Séronie-Vivien, M.M. Galteau, M.C. Carlier, A. Hadj-Aissa, A.M. Hanser, B. Hym, A. Marchal, O. Michotey, C. Pouteil-Noble, M. Sternberg, and A. Perret-Liaudet. Impact of standardized calibration on the inter-assay variation of 14 automated assays for the measurement of creatinine in human serum. Clin. Chem. Lab. Med. 43(11): 1227-1233 (2005).
15. J. Hailing, M.S. Petersen, P. Damkier, F. Nielsen, P. Grandjean, P. Weihe, S. Lundgren, M.S. Lundblad, and K. Brosen. Polymorphism of CYP2D6, CYP2C19, CYP2C9, and CYP2C8 in the Faroese population. Eur. J. Clin. Pharmacol. 61(7): 491-497 (2005).
16. G. Granerus, B. Lönnqvist, M. Källberg, and B. Kågedal. Day-to-day variation in urinary excretion of the histamine metabolite methylimidazoleacetic acid. Inflamm. Res. 47(Suppl 1): S52-S53 (1998).
17. B.K. Matuszewski, M.L. Constanzer, and CM. Chavez-Eng. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS-MS. Anal. Chem. 75(13): 3019-3030 (2003).
18. M.G. Scordo, E. Spina, M.L. Dahl, G. Gatti, and E. Perucca. Influence of CYP2C9, 2C19, and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin. Pharmacol. Toxicol. 97(5): 296-301 (2005).
19. U.A. Meyer. Pharmacogenetics and adverse drug reactions. Lancet 356(9242): 1667-1671 (2000).
20. J.A. Goldstein. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52(4): 349-355 (2001).
21. A.K. Daly. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam. Clin. Pharmacol. 17(1): 27-41 (2003).
22. L.K.W. Bertilsson. Interethnic differences in drug disposition and effects. In Interindividual Variability in Human Drug Metabolism, H.M. Pacifici and O. Pelkonen, Eds. Taylor & Francis, London, U.K., 2001, pp 15-74.
23. P.J. Wedlund. The CYP2C19 enzyme polymorphism. Pharmacology 61(3): 174-183 (2000).
24. J.F. Rogers, A.N. Nafziger, and J.S. Bertino, Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metab-olized drugs. Am. J. Med. 113(9): 746-750 (2002).
25. K. Kosuge, Y. Jun, H. Watanabe, M. Kimura, M. Nishimoto, T. Ishizaki, and K. Ohashi. Effects of CYP3A4 inhibition by dilti-azem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Drug Metab. Dispos. 29(10): 1284-1289 (2001).
26. J. Schmider, D.J. Greenblatt, L.L. von Moltke, and R.I. Shader. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. J. Clin. Psychopharmacol. 16(4): 267-272 (1996).
27. S. Ono, T. Hatanaka, S. Miyazawa, M. Tsutsui, T. Aoyama, F.J. Gonzalez, and T. Satoh. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19, and the 3A subfamily. Xenobiotica 26(11): 1155-1166 (1996).
28. F. Jung, T.H. Richardson, J.L. Raucy, and E.F. Johnson. Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases. Drug Metab. Dispos. 25(2): 133-139 (1997).
29. T.J. Yang, M. Shou, K.R. Korzekwa, F.J. Gonzalez, H.V. Gelboin, and S.K. Yang. Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochem. Pharmacol. 55(6): 889-896 (1998).
30. D.R. Abernethy, D.J. Greenblatt, M. Divoll, and R.I. Shader. Prolonged accumulation of diazepam in obesity. J. Clin. Pharmacol. 23(8-9): 369-376 (1983).
31. D.R. Abernethy, D.J. Greenblatt, M. Divoll, and R.I. Shader. Prolongation of drug half-life due to obesity: studies of desmethyl-diazepam (clorazepate). J. Pharm. Sci. 71(8): 942-944 (1982).
32. L. Pichard, G. Gil let, C. Bonfils, J. Domergue, J.P. Thenot, and P. Maurel. Oxidative metabolism of Zolpidem by human liver cytochrome P450S. Drug Metab. Dispos. 23(11): 1253-1262 (1995).